FIBROGEN INC - COMMON

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2023 Financial Results

24 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

03 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results

27 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

27 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

17 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Present at SVB Securities Global Biopharma Conference

02 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

28 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Third Quarter 2022 Financial Results

07 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management

07 Nov 2022 15:00:00 By Nasdaq GlobeNewswire

FibroGen to Participate at Stifel 2022 Healthcare Conference

01 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2022 Financial Results

24 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)

26 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2022 Financial Results

08 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2022 Financial Results

25 Jul 2022 06:00:33 By Nasdaq GlobeNewswire

FibroGen to Participate at William Blair Biotech Focus Conference 2022

01 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

08 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

FibroGen to Present at Jefferies Healthcare Conference

26 May 2022 06:00:00 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2022 Financial Results

09 May 2022 15:01:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2022 Financial Results

25 Apr 2022 06:00:00 By Nasdaq GlobeNewswire